 Aileron Therapeutics ALRN, the clinical-stage leader in the field of stabilized, cell-permeating peptides, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019. The dose-optimization Phase 1b portion of the Phase 1b2 clinical trial started dosing small cell lung cancer SCLC patients in September 2019. 